GlobeNewswire Inc | Nov 18, 2021 04:05PM EST

November 18, 2021

MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients lives, today announced plans to participate in the upcoming Piper Sandler Annual Virtual Healthcare Conference.

A recording of the fireside chat will be available beginning on Monday, November 22, 2021, at 10:00am ET. Interested parties may access the webcast on the Investors section of the companys website at: https://investors.sightsciences.com/

About Sight SciencesSight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform standards of care and improve patients lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the worlds most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Companys OMNI Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the worlds leading cause of irreversible blindness. The Companys TearCare System is commercially available today as a wearable, office-based thermal eyelid technology that enables the controlled application of localized heat to the eyelids. The Company has a 510(k) pending for the clearance of the TearCare System for an expanded indication for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). For more information, visit www.sightsciences.com.

OMNI and TearCare are registered trademarks of Sight Sciences. 2021 Sight Sciences. All rights reserved.

Media contact:Shay SmithHealth+Commerce707.971.9779shay@healthandcommerce.com

Investor contact:Philip TaylorGilmartin Group415.937.5406Investor.Relations@Sightsciences.com